Joseph Benenate, DO
Geriatric Medicine · Dallas, TXNPI 1851407019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 56.7% of the total.
Across 107 payments — averaging $12.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$748
- Aucta Pharmaceuticals, Inc.$369
- Avanir Pharmaceuticals, Inc.$56
- Otsuka America Pharmaceutical, Inc.$42
- UCB, Inc.$37
- Acadia Pharmaceuticals Inc$28
- plus $39 from 2 others
What the payments were for
- Food & beverage$1,319100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 65 | $748 |
| Aucta Pharmaceuticals, Inc. | 32 | $369 |
| Avanir Pharmaceuticals, Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| UCB, Inc. | 1 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Urovant Sciences Inc | 1 | $13 |
How this compares
$1,319 in reported general payments places this provider in the 80th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 516 | $152,368 |
| AptiomEslicarbazepine Acetate | 128 | $86,862 |
| Invega SustennaPaliperidone Palmitate | 24 | $79,604 |
| XifaxanRifaximin | 42 | $67,903 |
| SantylCollagenase Clostridium Hist. | 31 | $54,696 |
| NuedextaDextromethorphan Hbr/Quinidine | 75 | $52,950 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 147 | $37,171 |
| JardianceEmpagliflozin | 90 | $30,739 |
| GemtesaVibegron | 91 | $22,166 |
| TrulicityDulaglutide | 25 | $21,525 |
| Mirtazapine | 588 | $19,966 |
| RytaryCarbidopa/Levodopa | 23 | $19,769 |
| JanuviaSitagliptin Phosphate | 67 | $19,109 |
| Potassium Chloride | 408 | $18,712 |
| Memantine Hcl | 397 | $17,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $56 | $52,95075 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $748 | $22,16691 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Dallas
- Diana KerwinDallas$81K
- Jennifer AdamsDallas$1K
- Robert HaddoxDallas$1K
- Mauricio Gonzalez-AriasAustin$825K
- Eberenne IgbokwePearland$124K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
- George TaffetHouston$9K
- John CarrollCorpus Christi$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.